Business Context and Reporting Period
This Form 8-K is filed by Tivic Health Systems, Inc. (not Valion Bio, Inc.) on August 14, 2024. The report discloses the Company's financial results for the second quarter ended June 30, 2024, via a press release furnished as Exhibit 99.1.
Key Financial Metrics
The filing text provided does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being contained within the press release (Exhibit 99.1) but are not detailed in the body of this 8-K document.
Material Changes
No specific material changes versus the prior comparable period are quantified in this filing text. The document serves as a notification that Q2 2024 results have been issued.
Guidance, Outlook, and Risks
- Forward-Looking Statements: The filing includes standard disclaimers regarding forward-looking statements involving risks and uncertainties that could cause actual results to differ materially from expectations.
- Regulation FD: The information is furnished under Regulation FD and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Verify the correct registrant name is Tivic Health Systems, Inc. (Ticker: TIVC), as the input metadata incorrectly listed "Valion Bio, Inc."
- Review Exhibit 99.1 (the Press Release) to obtain actual financial figures for the quarter ended June 30, 2024.
- Confirm the Company's status as an emerging growth company and its implications for financial reporting standards.